A combination of two antiretroviral drugs is as effective as three drugs in people with HIV.

Compilation
Dolce’s research, promoted by the Wespeda Foundation and the Baiana Infectology Foundation, evaluates the effectiveness of a combination of two drugs dolutegravir and lamivudine (Dovato) V 229 people with advanced stage of HIVwho have not previously received antiretroviral treatment. This study decides that levels of viral suppression with these two drugs are similar to those of three-drug antiretroviral therapy in HIV-infected adults with advanced disease. These data were resolved in analysis at 48 weeks.

In the clinical trial, supported by ViiV Healthcare, they randomized participants to receive either a two-drug regimen (152 patients) or a three-drug regimen: DTG+TDF/XTC (77 participants).

Baseline characteristics of participants in the two treatment groups were similar. A 43% of participants had severe immunosuppression, with a CD lymphocyte content of less than 100 cells/ml. 61% of participants had an HIV viral load greater than 100,000 copies/mL, and 23% had a viral load greater than 500,000 copies/mL.

The results of the study showed comparable effectiveness of the two-drug regimen and the three-drug regimen – 82% and 80%, respectively.

The aim of the study was the proportion of participants with HIV viral load in plasma is less than 50 copies/ml. The results showed comparable effectiveness of the two-drug regimen and the three-drug regimen, while 82% and 80% of participants

respectively. Sayings The data were presented at the HIVGlasgow conference, which took place in Glasgow, Scotland from 11 to 13 November.

74% of participants in the two-drug group and 67% of the three-drug group who achieved a virological response had a viral load greater than 500,000 copies/mL. The change in CD4 count from baseline to week 48 showed an increase of 200 cells/μl.3 in the first group of participants and an increase of 177 cells/mm3 in the triple therapy group.

The study aimed to determine the proportion of participants with a plasma HIV viral load less than 50 copies/mL.

The study identified other secondary performance measures. He virus suppression time

And restoration of CD4 lymphocytes were similar between the two groups of patients. Safety through week 48 remained comparable between both groups and was consistent with known safety profiles. Both groups had similar rates of serious adverse events and immune reconstitution syndrome.